The PennZone

PHILADELPHIA, Oct. 22, 2024 ~ A recent study conducted by researchers at Children's Hospital of Philadelphia (CHOP) has shown the potential for rapid testing of cytokine levels to aid in distinguishing between different diseases with similar symptoms. The findings, published in the Journal of Allergy and Clinical Immunology, demonstrate the impact this testing can have on clinical practice.

The study, led by Dr. Michele P. Lambert, Medical Director of the Special Coagulation Laboratory and attending physician in the Division of Hematology at CHOP, focused on the use of serum cytokine panels in pediatric clinical practice. Cytokines are signaling proteins that regulate inflammation and coordinate immune responses.

During the COVID-19 pandemic, doctors faced a challenge in distinguishing between multisystem inflammatory syndrome in children (MIS-C) and acute, severe COVID-19 infection. Both conditions present with similar initial symptoms such as high fever and changes in blood pressure, but require very different courses of treatment.

Dr. Lambert explains, "We wanted to see what clinicians were able to do with this information if it was returned rapidly and whether results would change clinical decision making or muddy the waters and create confusion."

More on The PennZone

• Bold Beauty Project Celebrates Anniversary with Collaborative Exhibition at FIU's Miami Beach Urban Studios
• Pacific Emblem Company Launches "Happy 250th Birthday America" Collection and Proud Supporter of the Gary Sinise Foundation
• Black Lion Indie Film Festival Returns May 1–3, 2026 with Film, Art, Networking, and Opportunities for Emerging Creatives
• Bold Beauty Project Announces Exhibition at Palazzo Mora Venice, Italy
• Porter's Day Care Empowers Philadelphia's Future Through 45+ Years of Excellence

The study found that nearly 30% of clinicians changed how they managed disease in children after receiving cytokine level information. In 18.8% of cases, the diagnosis was changed or informed by the results, while management of the patient was changed or informed in 29.8% of cases.

One key finding was that specific disease states had clear cytokine patterns. For example, higher levels of interferon gamma (IFNg) and lower levels of interleukins 6 and 8 (IL-6 and IL-8) suggested a more robust inflammatory response, while a reverse in those levels indicated bacterial or viral sepsis.

Dr. Lambert emphasizes the potential life-saving impact of these results: "The results of a cytokine panel could potentially save lives: supporting antibiotics or immune suppression, but only if we have the results fast enough."

The study also highlights the importance of collaboration between clinicians and clinical laboratories in providing the best care for patients. As Dr. Lambert notes, "The evolution of our response time and our understanding of the value of these biomarkers demonstrates how important it is for clinicians and clinical laboratories to collaborate to provide the best care possible for patients."

With ongoing advancements in technology and understanding, rapid testing of cytokine levels has the potential to greatly impact clinical practice and improve patient outcomes. The study, titled "Serum Cytokine Panels in Pediatric Clinical Practice," was published online on September 18, 2024, with a DOI of 10.1016/j.jaci.2024.08.030.

For further information or inquiries, please contact Amanda DiPaolo Bradley at [insert contact information].

---

Show All News | Disclaimer | Report Violation